Crispr Therapeutics Ag (CRSP)

Nov 20, 2024

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? - Yahoo Finance

Nov 20, 2024

Nov 19, 2024

The Best Biotech Stocks to Buy - Morningstar

Nov 19, 2024

Nov 19, 2024

CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance

Nov 19, 2024

Nov 19, 2024

10 Best Genomics Stocks To Buy Right Now - Insider Monkey

Nov 19, 2024

Nov 19, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Large Increase in Short Interest - MarketBeat

Nov 19, 2024

Nov 17, 2024

CRISPR Therapeutics AG (CRSP): Among ARK Invest’s Top Stock Picks for 2024 - Insider Monkey

Nov 17, 2024

Nov 17, 2024

Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool

Nov 17, 2024

Nov 16, 2024

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Gene Editing Tools Market Size, Growth Opportunities, - openPR

Nov 15, 2024

Nov 15, 2024

First Week of July 2025 Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq

Nov 15, 2024

Nov 14, 2024

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference - The Manila Times

Nov 14, 2024

Nov 14, 2024

Van ECK Associates Corp Sells 78,228 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Nov 14, 2024

Nov 13, 2024

Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million - Investing.com India

Nov 13, 2024

Nov 13, 2024

Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million By Investing.com - Investing.com UK

Nov 13, 2024

Nov 13, 2024

Sumitomo Mitsui Trust Group Inc. Has $139.44 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Nov 13, 2024

Nov 13, 2024

Baillie Gifford & Co. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Nov 13, 2024

Nov 13, 2024

CRISPR Therapeutics (CRSP) Stock Analysis: An Unexpected Rise Amidst A Flat Market - Barchart

Nov 13, 2024

Nov 12, 2024

CRISPR Therapeutics' SWOT analysis: gene editing pioneer faces casgevy launch challenges - Investing.com India

Nov 12, 2024

Nov 11, 2024

Crispr Therapeutics Q3 EarningsNo Casgevy Revenue, But Plenty Of Optimism (NASDAQ:CRSP) - Seeking Alpha

Nov 11, 2024

Nov 11, 2024

(CRSP) Investment Analysis - Stock Traders Daily

Nov 11, 2024

Nov 11, 2024

What is Chardan Capital's Estimate for CRSP FY2024 Earnings? - MarketBeat

Nov 11, 2024

Nov 09, 2024

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 09, 2024

Nov 08, 2024

What is Leerink Partnrs' Forecast for CRSP FY2024 Earnings? - MarketBeat

Nov 08, 2024

Nov 08, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by ARK Investment Management LLC - MarketBeat

Nov 08, 2024

Nov 08, 2024

CRSP FY2024 EPS Reduced by Brookline Capital Management - MarketBeat

Nov 08, 2024

Nov 08, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Nov 08, 2024

Nov 08, 2024

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates - MSN

Nov 08, 2024

Nov 07, 2024

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times

Nov 07, 2024

Nov 07, 2024

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results - Simply Wall St

Nov 07, 2024

Nov 07, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat

Nov 07, 2024

Nov 06, 2024

Positive Long-Term Outlook for Crispr Driven by Casgevy and Diverse Gene Editing Portfolio - Morningstar

Nov 06, 2024

Nov 06, 2024

Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High? - MSN

Nov 06, 2024

Nov 06, 2024

CRISPR Therapeutics Sell rating reiterated on recent performance - Investing.com

Nov 06, 2024

Nov 06, 2024

Barclays Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat

Nov 06, 2024

Nov 06, 2024

Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform By Investing.com - Investing.com Canada

Nov 06, 2024

Nov 06, 2024

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 06, 2024

Nov 05, 2024

Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform - Investing.com

Nov 05, 2024

Nov 05, 2024

CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners - StreetInsider.com

Nov 05, 2024

Nov 05, 2024

Crispr Therapeutics earnings beat by $0.41, revenue fell short of estimates - Investing.com

Nov 05, 2024

Nov 05, 2024

CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4%Time to Sell? - MarketBeat

Nov 05, 2024

Nov 05, 2024

CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024

Nov 05, 2024

CRSPCRISPR Therapeutics AG Latest Stock News & Market Updates - StockTitan

Nov 05, 2024

Nov 05, 2024

CRISPR Q3: CASGEVY Expands Global Reach, $1.9B Cash Position as Losses Narrow | CRSP Stock News - StockTitan

Nov 05, 2024

Nov 04, 2024

CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average - Zacks Investment Research

Nov 04, 2024